The Indian stock market is currently experiencing a strong business environment, with both FII and domestic investors starting to invest in large numbers. Given the current situation, the mood of the Indian stock market is positive, providing shareholders with the opportunity to earn significant profits. In such times, some experts have chosen to invest in the pharmaceutical sector. Investec, a brokerage firm, has recommended investing in Orchid Pharma shares. Experts have given a ‘buy’ rating on Orchid Pharma shares and advised investing at a target price of INR 800. The company’s shares closed at INR 565.35 on December 7, 2023, and rose by 13.58% to INR 643 on December 8, 2023. On Monday, December 11, 2023, the shares were trading at INR 657, up by 0.94%.
According to the expert report, Orchid Pharma’s new management is focused on the company’s turnaround story and growth. Additionally, the company’s operating profit, or EBITDA, has doubled in the past three years. Furthermore, the company has significantly reduced its debt. According to the expert, the PLI project will strengthen Orchid Pharma’s integrity. The company will benefit from its US-based business in terms of API capabilities and development. According to the brokerage firm, Orchid Pharma’s sales are expected to have a 24% CAGR, EBITDA to have a 38% CAGR, and PAT to have a 49% CAGR from the financial year 2023-26. Orchid Pharma’s shares have increased by 10% in the past five trading sessions. In the last six months, the company’s shares have provided a 55% return to its investors. Over the past year, the company’s share price has increased by 66%.
Here is an English language HTML ordered list of information on stocks to buy:
- Stock: Orchid Pharma
- Rating: Buy
- Target Price: ₹800
- Closing Price on 7th December 2023: ₹565.35
- Closing Price on 8th December 2023: ₹643
- Closing Price on 11th December 2023: ₹657
- Management focused on turnaround story and growth
- EBITDA doubled in the past 3 years
- Significant reduction in debt
- PLI project to strengthen company’s integrity
- Expected sales growth of 24% CAGR, EBITDA growth of 38% CAGR, and PAT growth of 49% CAGR for FY 2023-26
- 10% increase in share price in the last five trading sessions
- 55% return to investors in the last six months
- 66% increase in share price in the last year
People Can Find This Information Useful for: stocks, buy, Indian stock market, business, FII, domestic investors, investment, positive mood, shareholders, bumper earnings, experts, pharmaceutical sector, shares, brokerage firm, Investec, Orchid Pharma, rating, target price, December 7, 2023, Friday, December 8, 2023, Monday, December 11, 2023, management, turnaround story, growth, operating profit, EBITDA, debt, PLI project, API capabilities, sales, CAGR, PAT CAGR, financial year 2023-26, returns, investors, stock price, increase.
Disclaimer: This is News Coverage with Opinions of Experts and Should Not Be Taken as Direct Market Buying Tip. Market is always subject to risk. We recommend taking our content as research before investing.
